Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 124 Show results per page	View Search Criteria \| Help With Results


1.		Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				CFEM345C2403 NCT00171847


2.		Effects of Granulocyte Colony-Stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				D-0140 NCT00169104

Last Modified: 12/4/2008 First Published: 3/1/2000


3.		Phase III Randomized Study of First-Line Trastuzumab (Herceptin) Alone Followed By Combination Trastuzumab and Paclitaxel Versus First-Line Combination Trastuzumab and Paclitaxel in Women With HER2-Overexpressing Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				SWS-SAKK-22/99 EU-99028, NCT00004935

Last Modified: 1/14/2009 First Published: 9/24/2003


4.		Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				SWOG-S0221 S0221, NCT00070564


5.		Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				Other				ID99-146 NCT00038402

Last Modified: 12/24/2007 First Published: 1/25/2006


6.		Phase III Randomized Study of Neoadjuvant Epirubicin Hydrochloride, Cyclophosphamide, and Docetaxel With Versus Without Capecitabine and/or Trastuzumab (Herceptin®) Followed by Surgery in Women With Stage I-III Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				GBG-GEPARQUATTRO GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002


7.		ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF104383 NCT00272987


8.		Trial of Myocet in Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 an over				Pharmaceutical / Industry				STM01-102 NCT00294996


9.		A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				Pharmaceutical / Industry				CR005143 NCT00338286

Last Modified: 10/25/2007 First Published: 9/23/2006


10.		Phase III Randomized Study of Adjuvant Trastuzumab (Herceptin®) Administered for 6 Months Versus 12 Months in Women With Nonmetastatic, Resectable Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				INCA-PHARE PHARE, INCA-RECF0146, EUDRACT-2006-000070-67, NCT00381901

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute